Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Intelgenx Technologies Corp (IGXT)

Intelgenx Technologies Corp (IGXT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Intelgenx Technologies Corp 6420 ABRAMS VILLE SAINT LAURENT A8 H4S 1Y2 CAN

www.intelgenx.com P: 514-331-7440

Sector:

Medical

INDUSTRY GROUPING:

Medical - Drugs

Description:

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The Company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastro-intestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films. The Company's research and development pipeline includes products for the treatment of osteoarthritis pain management, hypertension and smoking cessation.

Key Statistics

Overview:

Market Capitalization, $K 29,168
Enterprise Value, $K 37,438
Shares Outstanding, K 174,658
Annual Sales, $ 1,040 K
Annual Net Income, $ -9,930 K
Last Quarter Sales, $ 430 K
Last Quarter Net Income, $ -1,380 K
EBIT, $ -8,730 K
EBITDA, $ -7,960 K
60-Month Beta 2.47
% of Insider Shareholders 42.05%
% of Institutional Shareholders 0.00%
Float, K 101,214
% Float 57.95%
Short Volume Ratio 0.40

Growth:

1-Year Return 18.02%
3-Year Return -65.26%
5-Year Return -67.25%
5-Year Revenue Growth -42.86%
5-Year Earnings Growth 50.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 05/15/24
Next Earnings Date 05/28/25
Earnings Per Share ttm -0.07
EPS Growth vs. Prev Qtr 0.00%
EPS Growth vs. Prev Year 0.00%
Annual Dividend & Yield 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%

IGXT Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 0.00%
Return-on-Assets % -150.85%
Profit Margin % -954.81%
Debt/Equity -0.86
Price/Sales 29.17
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share -0.07
Interest Coverage -5.09
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar